| Bioactivity | RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 µM for dynamin I GTPase. RTIL 13 also targets pleckstrin homology lipid binding domain. RTIL 13 can inhibit receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively[1][2]. |
| Target | IC50: 2.3 µM (dynamin I GTPase) |
| Invitro | RTIL 13 inhibits receptor-mediated and synaptic vesicle endocytosis, with IC50s of 9.3 μM and 7.1 μM, respectively[2]. |
| Name | RTIL 13 |
| CAS | 1009376-10-6 |
| Formula | C30H55BrN2O3 |
| Molar Mass | 571.67 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang J, et, al. From Spanish fly to room-temperature ionic liquids (RTILs): synthesis, thermal stability and inhibition of dynamin 1 GTPase by a novel class of RTILs. New Journal of Chemistry. 2008 Jan; 32(1): 1-180. [2]. Ascent Scientific Launch Novel Dynamin Inhibitor Dyngo-4a™ with Children's Medical Research Institute and University of Newcastle. Tuesday, December 28, 2021. |
RTIL 13
CAS: 1009376-10-6 F: C30H55BrN2O3 W: 571.67
RTIL 13 is a potent inhibitor of dynamin GTPase, with an IC50 of 2.3 µM for dynamin I GTPase. RTIL 13 also targets plec
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.